Skip to main content
padlock icon - secure page this page is secure

The Therapeutic Potential of Neuro-EPO Administered Nasally on Acute Cerebrovascular Disease

Buy Article:

$68.00 + tax (Refund Policy)

Cerebrovascular disease is the third leading cause of death and disability in many countries of the first world because currently a safe and effective treatment is still not available for this disease. Cerebrovascular disease is the third leading cause of death in Cuba and the leading cause of disability, as it affects 50% of the population over 60 years. The mortality rate increases exponentially with age, doubling every five years. This tends to prevail in our country, where 14% of the population is over 60 years, with a life expectancy of close to 80. In this paper, we offer a critical opinion on the advantages of employing nasal Neuro-EPO over the more frequently used intravenous Erythropoietin as a neuroprotector for the treatment of acute ischemic stroke. The preclinical results obtained with this new molecule support a rapid delivery to the central nervous system, as well as its efficacy and safety in different animal models. Particular emphasis is made on the possibilities of this new drug in the development of novel treatments for chronic diseases and its potential preventive use in neurodegenerative and psychiatric diseases. It assesses comparatively, the state of the art in relation to the development achieved in our country and the prospects of the use of Neuro-EPO for the treatment and/or prevention of a disease that is virtually orphan of a specific treatment. Finally, recombinant human erythropoietin reaches the central nervous system with great difficulty through transmembrane diffusion or by saturable transport mechanisms, so Neuro- EPO would be an ideal candidate to develop its passage through extracellular pathways, specifically the nasal route
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Cerebrovascular disease; Choroid plexus; Erythropoietin; Nasal delivery; Neuro-EPO; Neuroprotection; Organum vasculosum; Sensory ganglionic; antiapoptotic; astrocytes; cerebral ischemia; cranial nerves; glycosylation; interleukin-1; moieties

Document Type: Research Article

Publication date: August 1, 2012

More about this publication?
  • Current Psychopharmacology publishes peer-reviewed expert review articles and single topic guest edited issues on all aspects of pre-clinical and clinical research in psychopharmacology. The journal aims to be the leading forum for expert review articles in the field. The journal also accepts high-level original research articles on outstanding topics of preclinical and clinical psychopharmacology. Data must be published for the first time in Current Psychopharmacology.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more